These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 3500265)

  • 1. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.
    Weber JS; Jay G; Tanaka K; Rosenberg SA
    J Exp Med; 1987 Dec; 166(6):1716-33. PubMed ID: 3500265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of two distinct primary T cell populations that secrete interleukin 2 upon recognition of class I or class II major histocompatibility antigens.
    Mizuochi T; Ono S; Malek TR; Singer A
    J Exp Med; 1986 Mar; 163(3):603-19. PubMed ID: 2936862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship among function, phenotype, and specificity in primary allospecific T cell populations: identification of phenotypically identical but functionally distinct primary T cell subsets that differ in their recognition of MHC class I and class II allodeterminants.
    Golding H; Mizuochi T; McCarthy SA; Cleveland CA; Singer A
    J Immunol; 1987 Jan; 138(1):10-7. PubMed ID: 2946773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GVHR elicited by products of class I or class II loci of the MHC: analysis of the response of mouse T lymphocytes to products of class I and class II loci of the MHC in correlation with GVHR-induced mortality, medullary aplasia, and enteropathy.
    Piguet PF
    J Immunol; 1985 Sep; 135(3):1637-43. PubMed ID: 2410497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
    Kim TS; Xu WS; Sun T; Cohen EP
    Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
    Karlhofer FM; Ribaudo RK; Yokoyama WM
    Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.
    Itoh T; Storkus WJ; Gorelik E; Lotze MT
    J Immunol; 1994 Aug; 153(3):1202-15. PubMed ID: 7517974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
    Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
    Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency analysis of class I MHC-reactive Lyt-2+ and class II MHC-reactive L3T4+ IL 2-secreting T lymphocytes.
    Heeg K; Steeg C; Schmitt J; Wagner H
    J Immunol; 1987 Jun; 138(12):4121-7. PubMed ID: 3108383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones.
    Pierres A; Naquet P; Van Agthoven A; Bekkhoucha F; Denizot F; Mishal Z; Schmitt-Verhulst AM; Pierres M
    J Immunol; 1984 Jun; 132(6):2775-82. PubMed ID: 6202760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts.
    Sprent J; Schaefer M; Gao EK; Korngold R
    J Exp Med; 1988 Feb; 167(2):556-69. PubMed ID: 2964497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY; Chou T; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.